Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 294.00
Bid: 292.00
Ask: 298.00
Change: -3.00 (-1.01%)
Spread: 6.00 (2.055%)
Open: 294.00
High: 294.00
Low: 294.00
Prev. Close: 298.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 May 2011 08:25

RNS Number : 5467G
Hutchison China Meditech Limited
13 May 2011
 



 

For filings with the FSA include the annex

For filings with issuer exclude the annex

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i

 

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

HUTCHISON CHINA MEDITECH LTD

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

 

 Slater Investments Ltd

 

4. Full name of shareholder(s)

(if different from 3.): iv

 

5. Date of the transaction and date on which the threshold is crossed or reached: v

12th May 2011

6. Date on which issuer notified:

12th May 2011

7. Threshold(s) that is/are crossed or reached: vi, vii

Above 6%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

 

Class/type of shares

if possible usingthe ISIN CODE

 

Situation previousto the triggeringtransaction

 

 

Resulting situation after the triggering transaction

 

Numberof Shares

 

NumberofVotingRights

 

Numberof shares

 

Number of votingrights

 

 

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

B11Y2X4

2,710,229

2,710,229

3,585,000

785,000

2,800,000

1.52%

5.41%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate xiii

 

Exercise/ ConversionPeriod xiv

 

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

 

% of votingrights

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Exerciseprice

 

Expirationdate xvii

 

Exercise/Conversionperiod xviii

 

Number of votingrights instrumentrefers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

3,585,000

6.93%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

 

Proxy Voting:

10. Name of the proxy holder:

 

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

13. Additional information:

14. Contact name:

 Ralph Baber

15. Contact telephone number:

 + 44 20 7220 9460

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOUBRASAVARR
Date   Source Headline
4th Jun 20189:41 amRNSFurther Fruquintinib FRESCO Trial Data - ASCO 2018
31st May 20187:00 amRNSTotal Voting Rights
30th Apr 20187:00 amRNSTotal Voting Rights
27th Apr 20181:52 pmRNSResults of Annual General Meeting
23rd Apr 20181:10 pmRNSGrant of Share Options under Share Option Scheme
23rd Apr 20181:05 pmRNSBlock Admission
29th Mar 20187:00 amRNSTotal Voting Rights
28th Mar 20187:00 amRNSVesting of awards under Long Term Incentive Plan
26th Mar 20187:00 amRNSAnnual Report & Notice of Annual General Meeting
21st Mar 20189:25 amRNSDirector's Share Dealing
20th Mar 20189:15 amRNSGrant of Share Options under Share Option Scheme
19th Mar 20187:10 amRNSDirector's Share Dealing
12th Mar 201811:22 amRNSPublication of Form 20-F
12th Mar 20187:02 amRNSFinal Results and Key Clinical Programs Update
6th Mar 20187:00 amRNSPhase Ib/II Trial of Epitinib in Glioblastoma
13th Feb 20187:01 amRNSEnrolment completed Ph III FALUCA Fruquintinib
5th Feb 20187:00 amRNSChi-Med to Announce 2017 Final Results
29th Dec 20177:00 amRNSBlock listing Interim Review
29th Dec 20177:00 amRNSTotal Voting Rights
15th Dec 20177:00 amRNSChi-Med Initiates Fruquintinib US Clinical Trials
1st Nov 20179:45 amRNSNotification of Major Holdings
1st Nov 20179:45 amRNSNOTIFICATION OF MAJOR HOLDINGS
31st Oct 20177:00 amRNSFRUTIGA, a Phase III trial of Fruquintinib
30th Oct 20173:30 pmRNSClosing of U.S. Public Offering of ADSs
27th Oct 201712:10 pmRNSChi-Med Announces Over-allotment Option
26th Oct 20177:00 amRNSChi-Med Announces Pricing Raising US$262 million
25th Oct 20177:00 amRNSChi-Med Announces Proposed Offering of ADSs
19th Oct 20179:20 amRNSNotification of Major Interest in Shares
17th Oct 20177:00 amRNSSavolitinib Shows Encouraging Clinical Activity
16th Oct 20177:00 amRNSChi-Med Reports Preliminary Phase II data
12th Oct 20177:30 amRNSAppointment of Director
29th Sep 20177:04 amRNSSavolitinib and Fruquintinib presentations at WCLC
29th Sep 20177:00 amRNSOral Presentations at CSCO Annual Meeting
29th Sep 20177:00 amRNSTotal Voting Rights
31st Aug 201710:15 amRNSDirector's Share Dealing
29th Aug 20177:00 amRNSStart of HMPL 689 Phase I Trial in China
22nd Aug 20179:00 amRNSDirector's Share Dealing
18th Aug 201710:50 amRNSDirectors' Share Dealing
15th Aug 201710:30 amRNSDirectors' Share Dealing
10th Aug 20179:35 amRNSDirector's Share Dealing
7th Aug 20179:45 amRNSDirectors' Share Dealing
31st Jul 20177:00 amRNSChi-Med Reports 2017 Interim Results
30th Jun 20177:00 amRNSTotal Voting Rights
29th Jun 20177:00 amRNSChi-Med to Announce 2017 HY Financial Results
29th Jun 20177:00 amRNSBlocklisting Six Monthly Return
29th Jun 20177:00 amRNSStart of Savolitinib Global PRCC Phase III Trial
22nd Jun 20177:00 amRNSChi-Med starts Ph I/II Trial of HMPL 453 in China
16th Jun 20179:57 amRNSDirector's Share Dealing
12th Jun 20177:00 amRNSFruquintinib NDA for Advanced CRC Filed with CFDA
6th Jun 20177:00 amRNSPhase III Fruquintinib Data presented at ASCO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.